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OBJECTIVES: To retrospectively review the patient demographics, disease profile 
and treatment outcomes of paediatric patients treated for ependymoma at our 
institution. 
 
STUDY DESIGN AND METHODS: 51 eligible patients were treated between 
1980 and 2013.  The median age at presentation was 6 years.   The majority of 
patients were male (66,7%), had infratentorial tumours (62,7%) and had low-grade 
tumours (70,6%).  Gross total resection (GTR) was achieved in 22 patients (43,1%).  
Thirty-eight patients received adjuvant radiotherapy (76,5%) and 10 (19,6%) 
received adjuvant chemotherapy. 
RESULTS: The 5-year overall survival (OS) was 63,3 % (median follow up of 46 
months).  The 5 year progression free survival (PFS) was 50,70%.  Seventeen 
(33,3%) patients experienced treatment failure, of which 13 (76,5%) represented 
local failure. The median time to first relapse was 20 months. The 5 year PFS for 
children > 3 was 50,0 % and 27,7% for children ≤ 3 years of age (p = 0.0356). GTR 
had a superior 5-year OS of 73,9% over subtotal resection with a value of 56,7% (p = 
0.0016).  Similarly an improved 5-year PFS of 70,3% versus 29,1% was observed 
with GTR over subtotal resection (p = <0.0001). Patients who received adjuvant 
radiotherapy (RT) had significantly better outcomes than those in whom RT was not 
given (p = <0.0001, 5 year OS of 69,7% versus 37,5%).   
CONCLUSION:  This review confirms the finding that GTR is associated with 
improved outcomes and that adjuvant radiation therapy positively impacts survival. 
The worse outcomes in the younger age group requires further evaluation and 










OBJECTIVES OF LITERATURE REVIEW 
The objective of this literature review is to provide the reader with background 
information on the topic of the outcomes of paediatric patients treated for  
ependymoma and justification for the research I have undertaken.  I will present 
work already published in this field.  Comparisons will be made through analysis of  
previously published data on this topic and the findings of this study.  This may 
allow identification of what is new, different or confirmatory and may identify areas 
where further research is required.  
LITERATURE RESEARCH STRATERGY 
For this literature review, articles relating to paediatric ependymoma outcomes were 
sought using the following search engines; PubMed, Google, and Google 
Scholar, provided through the University of Cape Town library resources.  Articles  
were chosen based on relevance to the topic under review.  Only publications in  
English were considered for the literature review. 
In the last few decades, the majority of published literature on paediatric 
ependymoma consisted of case reports and small, single institution retrospective 
analyses.  Due to the rarity of this tumour, these series frequently had small numbers 
of patients, often failing to reach numbers of significant statistical power.  More 
recently the large paediatric co-operative groups have been able to publish larger 
series and randomized controlled trials, which are superior in the hierarchy of 
evidence.  A systematic review of intracranial ependymomas has been previously 
published.   The majority of literature on this topic has been from developed 
countries.  There is little available literature published to give insight on paediatric 
ependymoma in the African setting or in other developing countries. 
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INTERPRETATION OF LITERATURE 
In order to understand and discuss the results of the current study, a detailed review 
of the available literature on this topic was performed and discussed.  This literature 
review will summarise and form discussions around the following sub headings:  
a) Background information
b) Epidemiology
c) Histological grading and cytogenetics
d) Treatment, outcomes and treatment related prognostic factors
e) Patient and tumour related prognostic factors
f) Challenges in paediatric neuro-oncology in low/middle income countries
g) Conclusion
a) BACKGROUND
Ependymomas are a group of neuroepithelial tumours that arise within or adjacent to  
the ependymal lining of the ventricular system.  Less commonly these tumours can  
occur within the brain parenchyma, arising from rests of fetal ependymal cells during 
development.   
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The aetiological factors that play a role in the development of these tumours are not 
fully understood.  It was previously postulated that exposure to the simian virus 40  
(SV40) could be a risk factor for development of ependymoma tumours.  This was  
based upon identification of the virus in tumour tissue.   However a causal 
relationship has not been confirmed 1.  An increased association of intramedullary
spinal cord ependymoma has been reported in patients with neurofibromatosis 2 
(NF2) 2.
Pevney and Rao reported that ependymal cells are remnants of the proliferative  
ventricular zone and they hypothesized that these cells are adult multipotent stem 
cells.  This was supported by the fact that ependymomas express both neuronal and 
glial markers 3.  It is postulated that because ependymal cells are maintained as
proliferating neural progenitors beyond the postnatal period, this leaves them  
susceptible to oncogenic transformation 4.
b) EPIDEMIOLOGY
Ependymal tumours are an uncommon group of tumours representing  
approximately 5,7% of all primary brain and CNS tumours in children aged 0- 14 
years, according to the latest data by CBTRUS 5.  Ependymomas represent
approximately 6% of all intracranial CNS tumours and 25% of all primary spinal  
cord tumours in the paediatric age group  6.   
The median age at presentation is between 4 and 7 years of age 7,8,9.  The majority
of studies show a slight male predominance 9,10,11.  The most common location for
ependymoma is the infratentorial compartment (intracranially).  These tumours occur 
less commonly in the supratentorial region or the spinal cord 8,12,13. Low grade
tumours (grade 2) form the vast majority of this group of tumours in the paediatric  
age group 12,13.  Disseminated disease at diagnosis is relatively uncommon,
occurring in <18% of patients at diagnosis 14,15.
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c) HISTOLOGICAL GRADING AND CYTOGENETICS
Bailey and Cushing 16 first recognized ependymomas as a distinct entity in 1926.
The 2007 World Health Organization (WHO) classification of tumours of the central 
nervous system has classified ependymomas into 3 grades.  WHO grade I includes 
myxopapillary ependymoma and subependymoma.  WHO grade II includes classic 
ependymoma and WHO grade III includes anaplastic ependymomas 17.  
Ependyoblastomas are highly malignant tumours that were previously considered as 
a variant of ependymoma.  These tumours are however now classified in the group of 
primitive neuroectodermal tumours.  In 2016, the WHO released the new 
classification of tumours of the central nervous system.  This classification sees the 
addition of a genetically defined ependymoma subtype known as RELA fusion 
positive ependymoma.  This variant forms the majority of supratentorial tumours in 
children.  Another modification to the 2016 classification of ependymoma is the 
removal of the cellular variant of classic ependymoma, as it was considered to 
overlap extensively with standard ependymoma.18
Ependymomas are a heterogeneous group of tumours that show variability in their  
clinical behavior and outcome.  The difficulty in predicting tumour behavior and  
outcome in these patients based on clinical and histological factors has led to the  
exploration of biological and molecular markers as well as genomic understanding of 
these tumours.  In the last decade, strides have been made in this regard and findings  
are influencing the management and prognostication of this group of patients.   
Cytogenetic studies have shown numerous chromosomal aberrations in ependymal 
tumours.  The most common aberration, occurring in 30-50% of tumours, is  
that of chromosome 22.  This includes monosomy 22 as well as deletions of  
22q  4.  Hirose et al reported on different patterns of chromosomal aberrations in
relation to tumour location.  Gain of 1q with losses on 6q, 9 and 13 were the 
common aberrations in intracranial tumours while gains on chromosome 7 with 
various other chromosomal abnormalities including frequent loss of 22q occurred 
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almost exclusively with spinal cord tumours.  This suggests that spinal cord tumours 
progress along different pathways than that of intracranial ependymomas 19.
Recently two distinct subtypes of posterior fossa ependymomas have been identified.  
These are known as Subtype A (CIMP +) and B (CIMP -).  These two subtypes 
differ in the age of the patient at presentation, location of the tumour, biological 
signaling pathways, genomic instability and prognosis.  Subtype A tends to occur in 
younger patients.  Most of the patients in this group are male (70%) and the tumours 
frequently are found extending into the cerebellopontine angle.  Tumours in this 
group have relatively little genomic instability.  Gain of chromosome 1 or loss of 
chromosome 22 occur frequently in this group.  In contrast, tumours of Subtype B 
predominantly occur in older patients and are usually located in the spinal cord or 
midline of the cerebellum.  In contrast to Subtype A, tumours of Subtype B have a 
much higher degree of genomic instability with extensive chromosomal aberrations.   
Prognostically, Subtype A tumours have a worse clinical outcome then those of  
Subtype B.  56% of patients belonging to the Subtype A group will develop  
recurrence and  35% will die of their disease within 5 years compared to Subtype  
B, where 25%  of patients will develop recurrence while 5% will die of their disease 
within 5 years 4.  The importance of this distinction of ependymomas into the two
subtypes has therapeutic implications.  Cytotoxic therapy functions by promoting 
damage to DNA.  This induces cancer cells with mutations and disorganized 
genomes to undergo apoptosis.  With the understanding that Subtype A (CIMP +) 
tumours have a nearly normal genetic code, it is thus not surprising that cytotoxic 
therapy based on DNA damage has shown no efficacy in clinical trials. 
The recent publication of a molecular classification of ependymal tumours in 2015 
 by K.Pajtler and H Witt, classified ependymomas into 9 distinct molecular  
subgroups using DNA methylation profiling20 . These  molecular
subgroups are genetically, epigenetically, transcriptionally, demographically and 
 clinically distinct.  There are 3 subgroups within each anatomical compartment of 
 the CNS, which includes spine, infratentorial and supratentorial).  This molecular  
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classification has proven to outperform the current histopathological classification 
 with regard to clinical associations and risk stratification of patients. The  
supratentorial compartment consists of the supratentorial subependymoma (balanced 
genome), the supratentorial anaplastic ependymoma (YAP1- fusion) and the  
supratentorial anaplastic (RELA-fusion) subgroups.  The subgroups of the  
infratentorial compartment include posterior fossa subependymoma (balanced  
genome), the posterior fossa anaplastic ependymoma (balanced genome) and the 
 posterior fossa anaplastic ependymoma (chromosomal instability).  Spine 
 subependymoma (6q deletion), spine myxopapillary ependymoma (chromosomal 
instability) and spine anaplastic ependymoma (NF2 mutation) are the 3 molecular 
 subgroups of spine ependymomas.  The subgroups that predominantly occur in 
 children include the posterior fossa anaplastic ependymoma (balanced genome), the 
 supratentorial anaplastic ependymoma YAP1- fusion and the supratentorial 
 anaplastic RELA-fusion subgroup.  Patients within the supratentorial anaplastic 
 RELA-fusion and posterior fossa anaplastic ependymoma (balanced genome) 
 subgroup have a poor prognosis with a 5 year PFS of 29% and 33% respectively and 
a 5 year OS of 75% and 68% respectively.  All the other molecular subgroups 
 showed a varied 5 year PFS of between 50% and 100% and all had a 5 year OS of 
100%.  
This new molecular classification of ependymomas will be of value in the design of 
future prospective clinical trials that tailor patient treatment according to risk  
stratification.  It will allow evaluation of adjuvant therapies such as radiotherapy, 
 chemotherapy and molecular targeted therapies in the context of specific molecular 
 groups.  This will ultimately help treating physicians tailor treatment accordingly 
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 and aim to improve the outcomes of patients diagnosed with these tumours.  
 
 
d)  TREATMENT, OUTCOMES AND TREATMENT RELATED PROGNOSTIC 
FACTORS 
The treatment of ependymoma involves multimodality treatment by a 
multidisciplinary team.  Surgery is the primary treatment modality.  Maximal safe 
surgical resection is aimed for by neurosurgeons with special care not to compromise 
neurological and functional outcome.  Extent of resection has been validated as one 
of the most important prognostic factors.  Van Veelen-Vincent et al reported superior 
outcomes in paediatric pateints treated for intracranial ependymoma between January 
1980 and December 1998  in whom a gross total resection (GTR) was achieved 10.  
The 5 year OS rate was 80% in the completely excised tumour group compared to 
51% for incomplete resection group (p value <0.03).  The 5 year event free survival 
(EFS) was 53% in the completely excised tumour group compared to 33% in the 
incomplete resection group (p value <0.04) 10.  Numerous studies have shown 
similair findings of an OS and prgrssion free survival (PFS)/EFS benefit with gross 
tumour resection 11,14, 21,22.  A PFS benefit, but no OS benefit was demonstrated in 
some publications 7,23.   
The importance of a total resection has led to the investigation of second look 
surgery in order to achieve a GTR.  Second look surgery can be perfomed 
postoperatively after primary surgery when residual tumour has been confirmed by 
postoperative imaging.  Alternatively it can be done after adjuvant chemotherapy in 
patients with residual tumour after primary surgery to facilitate ease of resectability 
by the possible cytoreductive effect of chemotherapy.  Massimino et al published 
results showing that second-look surgery proved feasible with no major morbidity 
and local tumor control was comparable in patients undergoing 1 or more resections 
24.    
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It must be noted that interpretation of published data on extent of resection is greatly 
influenced by the definitions used for GTR, near total resection (NTR) and subtotal 
resection (STR), both as described from the neurosurgical report as well as from 
neuro-radiological findings.    This has made data comparison and interpretation 
difficult over the years as varying definitions have been used in different studies.  A 
standardised definition for the extent of tumour resection (based on postoperative 
imaging) needs to be developed so accurate comparisons can be made.  
The role of postoperative radiotherapy is well established and is based on historic 
retrospective studies, which have shown superior progression free survival in 
patients who received adjuvant radiation therapy compared to surgery alone 14,25,26.
In the past craniospinal irradiation was the favoured radiotherapy volume chosen for 
paediatric ependymoma due to the risk of spinal seeding associated with this tumour.  
Currently, treatment guidelines recommend localized radiation therapy in patients 
with non-metastatic disease.  Numerous studies support the finding that the major 
route of failure for localized ependymomas is a local recurrence 9,14,27,28.  In
addition the low rate of metastatic relapse 9,14,29 does not warrant craniospinal
irradiation. 
The role of chemotherapy is not well established in the treatment of ependymoma.  
Grundy et al published results on paediatric intracranial ependymoma patients who 
were 3 years old and younger at diagnosis and received chemotherapy 
postoperatively in order to defer radiotherapy thus preventing the neurocognitive 
effects on the developing brain.  The 5-year incidence of freedom from radiotherapy 
for patients with non-metastatic disease was 42%.    However this came at a cost of a 
high rate of recurrence.  Fifty of the 80 (62,5%) patients with non-metastatic disease 
progressed and 9 out of 9 (100%) of the patients with metastatic disease progressed.  
The median time to progression for all patients was 1,6 years.  The 3 year event free 
survival reported in this study was 47,630.  This compares unfavourably to the EFS
of 74,7%  reported by Merchant et al in a study looking at immediate adjuvant 
radiotherapy in children 3 years and younger 31.  Merchant et al also showed that
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although the mean IQ of children less than 3 at the start of radiation therapy was 
lower than children over the age of 3, the IQ of the younger children improved over 
time.  The level of function and lack of treatment related effects in the younger and 
more vulnerable group with high dose radiation therapy is encouraging 31. 
 
The five-year overall survival rates for paediatric patients treated for ependymoma 
range from 44% to 79% 7,8,9,10,29,37. The five-year progression free survival rates 
range from 25% to 74% 9,11,30,42. Local failure remains a major problem with 
ependymal tumours.  Recurrence is noted in 27% to 65% of patients 7,10,14,29.  
 
e)  PATIENT AND TUMOUR RELATED PROGNOSTIC FACTORS 
 
Many publications on the prognostic factors related to ependymal tumours are 
retrospective in nature and include limited numbers of patients due to the low 
incidence of this tumour.  In addition, many of these studies span a few decades, 
which hampers the interpretation of the results due to changes in histological grading 
systems, diagnostic evaluation and treatment policies.  Therefore interpretation of 
definitive prognostic factors proves difficult.  Below, the literature regarding 




Treating ependymomas in the paediatric setting presents a challenge for the 
 treating physicians especially for the younger paediatric population who are less 
then 3 years of age.  Maximum safe surgical resection followed by radiation therapy 
is the accepted treatment for majority of patients who present with these tumours.  
However children who receive radiation therapy are at risk of developing varying 
degrees of neuro-cognitive impairment and endocrinopathies due to the effect of the 
radiation on the immature, rapidly growing brain 32,33,34.  These adverse effects 
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were thought to be much more deleterious in children under the age of 3  years.  
Trials that have investigated the use of chemotherapy to delay radiation therapy have 
had inferior results to those achieved for patients treated with immediate 
postoperative radiation therapy 35,36.  Currently, it is accepted practice to treat 
children below the age of 3 years with conformal radiotherapy.  Merchant et al 
reported that conformal radiotherapy achieved high rates of disease control in 
pediatric patients with ependymoma and resulted in stable neurocognitive outcomes 
31.  
 
Improved outcomes have been documented in the older paediatric population treated 
for ependymoma 9,27,37.  It has been postulated that the difference in cytogenetic 
aberrations between younger and older patients may be responsible for the age 
related outcome 19.  High levels of expression of the genes LDHB and STAM in 
younger patients have been thought to lead to increased cellular proliferation that 
could account for the unfavourable outcome seen in younger patients 38.  In addition, 
Comi et al reported that younger patients presented later and with bigger tumours 
than older children 39.  Lastly an association between younger age with high-grade 
(anaplastic) tumours has been suggested 37. 
 
2. Histological grade 
Much controversy exists regarding the influence of tumour grade on survival. 
One of the major problems regarding tumour grading is the discrepancy 
between pathologists.  Robertson PL et al showed discrepancies between the 
institution’s diagnosis and the centralized review diagnosis, present in 69% of 
cases of that study 7.  Another factor to consider, is that until the revision of 
the WHO classification of 1993, anaplasia was not used to classify grading.  
Additionally ependymoblastomas , which have an aggressive behaviour were 
previously classified as ependymomas and have since been classified as 
primitive neuroectodermal tumours 40.   The last important factor to consider 
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is that a single grading system needs to be used in all studies to allow 
comparison and consensus on the definition of anaplasia needs to reached by 
neuro-pathologists.  
Various published papers have failed to show a correlation between tumour 
grading and outcomes 10,41,42.  Conversely the following papers 
demonstrated a progression free survival benefit in low-grade tumours 9,21,43 
.  Korshunov et al,  in 2004, suggested both a PFS and OS benefit with low 
grade tumours when compared to high grade (anaplastic) tumours 23.  
3. Tumour location 
Ependymomas located in the spinal region are associated with improved 
survival outcomes when compared to intracranial tumours 8,12,29.  The 
prognostic significance of infratentorial versus supratentorial tumour location 
is less clear.  Some literature has suggested that supratentorial ependymomas 
have  a worse prognosis 12,29,23,44.  Reasons suggested for worse outcome of 
the supratentorial location is that ependymomas in this region often have 
peripheral infiltrative growth into the brain parenchyma 45 and are less often 
completely encapsulated, making complete surgical resection difficult 46.   
Cage et al  reported that infratentorial tumours have better outcome due to the 
fact that lesions in this region cause symptoms sooner then their 
supratentorial counterparts and thus treatment can be initiated earlier 47. 
Conversely the following trials have suggested worse outcomes with 
infratentorial ependymomas 42,48 .  Numerous reports show no difference in 
survival between infratentorial and supratentorial tumours 8,27,49,50].  
In addition, within each tumour site, subgroups have been identified that 
make surgical resection difficult.  Ernestus et al identified midline 
supratentorial tumours as a subgroup associated with a lower resection rate 
and higher operative mortality 51.  Lateral recess tumours which originate 
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from the lateral part of the fourth ventricle infratentorially pose a difficulty in 
obtaining a good resection as they tend to displace or involve neurovascular 
structures 52.   
Cytogenetics has deepened our understanding of the differences between 
spinal and intracranial ependymomas as distinct entities and could account 
for the difference in outcomes of the two tumour locations.  Spinal 
ependymomas display a common genetic signature with high levels of 
expression of HOXB5, PLA2G5 and ITIH2.  CDKN2A is amongst the most 
frequently expressed genes in spinal ependymoma when compared to 
intracranial tumours 38. Compared to spinal tumours, intracranial 
ependymomas show high expression of NF2.  This could be due to NF2 gene 
deletion or mutations that are predominantly found in spinal ependymomas 2 .  
In addition, gain of 1q and losses on 6q,9 and 13 are frequent with 
intracranial ependymomas, whereas gains on chromosome 7 occur almost 
exclusively in spinal ependymomas 38.  
 
4. Staging 
Spread of ependymoma occurs predominantly through local invasion and less 
commonly by cerebrospinal fluid dissemination.  Disseminated disease at 
diagnosis is relatively uncommon.  Previously published literature has 
documented disseminated disease at diagnosis  in 5-17% of tumours 
9,14,27,44.  
A 1996 publication by Rezai et al, studied the prognostic criteria for 
dissemination in patients diagnosed with ependymomas.  In the total cohort, 
11,4% of patients developed dissemination and this was associated with 
increased mortality.  It was reported that patients at risk of dissemination 
during the course of their disease were younger patients, patients who did not 
have a gross tumour resection, patients with high grade or myxopapillary 
tumours and patients with high proliferation indices 53. 
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Agaoglu FY et al showed an overall and disease free survival benefit for 
patients with non- metastatic disease compared to those with metastatic 
disease 9.  
f) CHALLENGES IN PAEDIATRIC NEURO ONCOLOGY IN LOW MIDDLE 
INCOME COUNTRIES 
Paediatric neuro-oncology management is complex.  It relies on a well functioning 
health care system with a specialised paediatric oncology centre with the relevant 
specialists and sub specialists, support staff , as well as an infrastructure and physical 
resources needed for the management of these tumours.  Many low/middle income 
countries are lacking in the expertise and resources available for paediatric neuro-
oncology management when compared to developed nations. Studies done in the 
United States of America have estimated that the cost of hospitilisation, surgery, 
chemotherapy, radiation therapy, labarotory studies and pharmacy services  amounts 
to $32000 - $45000 for the first year after a brain tumour diagnosis, with subsequent 
annual costs of $4000 - $8000 54.  This represents an unrealistic burden for 
developing countries where an estimated 26% of the population survives on less than 
$US 1 per day 55.  The move to molecular subgrouping of ependymomas in order to 
tailor treatment accordingly, will add to the already huge financial burden 
experienced by developing countries in treating these tumours due to the high cost of 
biological/molecular testing. Another major challenge in developing countries is that 
the ratio of medical specialists to population is poor.  As an example, in 2007, the 
number of paediatric neurosurgeons in selected countries throughout the world was 
estimated and nine out of then ten surveyed countries  that failed to meet the 
minimum recommended ratio of paediatric neurosurgeons were in developing 
regions 56.  The lack of resources in developing countries continues to be a 
challenge.  Recent studies estimate thst 29 countries in Africa and 13 in Asia 
completely lack radiotherapy capabilities 57,58 and radiotherapy forms an intergral 
part of treatment of brain tumours.  Analysis of the WHO’s 2010 international survey 
of medical devices showed that high income countries have 142 times the MRI 
capability of low income nations, 53 times the CT scan capability and 555 times the 
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PET CT scan capability, as adjusted for population 59.  Lastly the development of 
cancer registries in developing countries has been substandard.  Cancer registries 
provide information on epidemiological patterns of cancer  that are endemic to 
particular regions or populations, provide information on disease burden, identify 
possible disease causes and help establish  priorities for combatting cancer in 
resource constrained areas.  Data from 2006 estimate  that only 8% of the population 
in Asia, 11% in Africa and 21% in Latin America are covered by cancer registries.  
This is in stark contrast to 99% of the population in the United States of America and 
Canada and 86% in Australia and New Zeland 60. 
 
g)  CONCLUSION 
Ependymomas represent a heterogenous group of tumours.  Determining prognostic 
factors that impact on survival for this group of tumours over the decades has 
resulted in some conflicting results.  Complete resection of tumour, older patient age  
and non metastatic ependymoma have been regarded as favourable prognostic 
factors.  Tumour location (supratentorial versus infratentorial) and histological 
grading still remains controversial with conflicting results.  Cytogenetics looks to be 
the future in determining prognostication of these tumours and determining 
treatment.   
Further research is needed in this field with international collaboration required in 
order to be able to recruit the required numbers of patients for future studies.  
Consensus on definitions used by neuropathologists for tumour grading and for 
definitions on extent of resection by neuro surgeons and neuro radiologists is needed.  
Randomised controlled studies as well as investigation into genetic subtyping will 
further contribute to our understanding of this tumour and its behaviour and will 
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OBJECTIVES: To retrospectively review the patient demographics, disease profile 
and treatment outcomes of paediatric patients treated for ependymoma at our 
institution. 
 
STUDY DESIGN AND METHODS: 51 eligible patients were treated between 
1980 and 2013.  The median age at presentation was 6 years.   The majority of 
patients were male (66,7%), had infratentorial tumours (62,7%) and had low-grade  
tumours (70,6%).Gross total resection(GTR) was achieved in 22 patients (43,1%).  
Thirty-eight patients received adjuvant radiotherapy (76,5%) and 10 (19,6%) 
received adjuvant chemotherapy. 
RESULTS: The 5-year overall survival (OS) was 63,3 % (median follow up of 46 
months).  The 5 year progression free survival (PFS) was 50,70%.  Seventeen 
(33,3%) patients experienced treatment failure, of which 13 (76,5%) represented 
local failure. The median time to first relapse was 20 months. The 5 year PFS for 
children > 3 was 50,0 % and 27,7% for children ≤ 3 years of age (p = 0.0356). GTR 
had a superior 5-year OS of 73,9% over subtotal resection with a value of 56,7% (p = 
0.0016).  Similarly an improved 5-year PFS of 70,3% versus 29,1% was observed 
with GTR over subtotal resection (p = <0.0001). Patients who received adjuvant 
radiotherapy had significantly better outcomes than those in whom RT was not given 
(p = <0.0001, 5 year OS of 69,7% versus 37,5%).   
CONCLUSION:  This review confirms the finding that GTR is associated with 
improved outcomes and that adjuvant radiation therapy positively impacts survival. 
The worse outcomes in the younger age group requires further evaluation and 







Ependymomas are classified as glial tumours and arise from ependymal cells lining 
the ventricle of the brain and central canal of the spinal cord.  They constitute 
approximately 8 and 25 % of all paediatric intracranial and spinal cord tumours 
respectively [1].   
 
Despite improvements in neuro- radiological imaging, micro-neurosurgical  
 
techniques and radiotherapy planning and delivery, ependymomas continue to be  
 
associated with significant morbidity and mortality. The overall 5-year survival rate  
 
for both intracranial and spinal ependymomas in the paediatric population is reported  
 
to range between 55 and 65% [2,3].  Ependymomas are a heterogeneous group of  
 
tumours that show variability in their clinical behaviour and outcomes thus making  
 
treatment of these tumours challenging for physicians.  The difficulty in predicting  
 
tumour behaviour and outcome in these patients based on clinical and histological  
 
factors has led to the exploration of biological and molecular markers as well as  
 
genomic studies of these tumours.  The new molecular classification of  
 
ependymomas [4] will allow patient treatment to be tailored according to risk  
 
stratification.  It will allow evaluation of adjuvant therapies such as radiotherapy, 
 
 chemotherapy and molecular targeted therapies in the context of specific molecular 
 
 groups.  This will ultimately help treating physicians tailor treatment accordingly 
 




There is a paucity of data from the developing world, including South Africa, with 
regards to outcome following management of these tumours. The purpose of this 
study was to report on the demographic profile, management trends and outcome of 
paediatric ependymomas in a single institution over a 33-year period. 
 
MATERIALS AND METHODS 
The Groote Schuur Hospital Radiation Oncology electronic patient registry (EPR) 
and the National Health Laboratory Service (NHLS) database were used to identify 
all cases of histologically confirmed ependymoma seen at the Groote Schuur 
Hopsital (GSH) / Red Cross Children’s Hospital (RCCH) complex between January 
1980 and December 2013.  Patients were eligible for the study if they had a 
histological diagnosis of ependymoma and were between the ages of 0 and 13 years 
at the time of diagnosis.  Patients were required to have received all or part of their 
treatment at the GSH/RCCH complex.  Patients with a histological diagnosis of 
ependymoblastoma were excluded.   
 
The University of Cape Town, Faculty of Health Sciences Human Research Ethics 
Committee granted approval for this research.  The medical folders of all eligible 
patients were reviewed for information relating to patient and tumour characteristics, 
treatment received, outcome and follow up.  
 
During the study period, all treatment decisions were made in a multidisciplinary 
meeting involving paediatric oncologists, neurosurgeons, radiologists, anatomical 
pathologists, endocrinologists and radiation oncologists.  The major factors that 
played a role in the treatment decision-making were the patient’s age, Eastern 
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Cooperative Oncology Group (ECOG) or Karnofsky performance status, tumour 
location, histological grade and extent of surgical resection. 
Imaging of the brain and whole spine with a CT scan or magnetic resonance imaging 
(MRI), as well as cytological assessment of cerebrospinal fluid (CSF) were used to 
assess for evidence of metastatic disease.  The histopathological grade was based on 
the World Health Orginisation (WHO) classification system [5].  Grade 1 tumours 
include subependymoma and myxopapillary ependymoma.  Grade II tumours refers 
to classic ependymoma.  These 2 grades are considered benign.  Grade III 
ependymoma includes anaplastic ependymoma (malignant).  
The extent of surgical resection was determined primarily using postoperative 
imaging (MRI and or CT scan) with contrast enhancement; however the 
neurosurgeons operative report was used where imaging was not available.  Gross 
total resection (GTR) included no enhancement on contrast enhanced postoperative 
imaging.  Near total resection (NTR) was defined as residual tumour measuring 
1,5cm3 or less and subtotal resection was defined as tumour measuring more than 
1,5cm3.  Biopsy only refers to cases where the neuro-surgeon has taken a biopsy 
sample with no debulking and the postoperative imaging confirms this. 
External beam radiotherapy was delivered using a Cobalt 60 machine or a linear 
accelerator.  Proton therapy (cyclotron) was used in 4 cases for the radiotherapy 
boost between the period of 1998 and 2002.  During the study period, there was a 
shift in the radiation technique being used for the treatment of these patients.  
Craniospinal irradiation (CSI) with a local boost was the favoured treatment 
technique in the earlier years of the study.  This changed to a localized radiation 
therapy technique post 1991. 
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Carboplatin, Vincristine and Etoposide were the agents used in patients who received 
chemotherapy as part of their treatment.  It was used in the setting of delaying 
radiation therapy in patient’s ≤ 3 years of age prior to 2014. 
 
Statistical calculations were performed using Prism Graph pad (version 6.00; 
Graphpad softwareR, San Diego, Cal).   Overall survival (OS) was defined as the 
time from date of pathological diagnosis till date of death or date of last contact for 
the patients lost to follow up.  Progression free survival (PFS) was defined as the 
time from date of pathological diagnosis to the date of progression or relapse.  The 
Kaplan–Meier method was used to generate survival curves.  The log rank test was 
used to compare the survival outcomes by age, gender, location, histological grade, 




There were a total of 58 patients diagnosed with ependymoma during the study 
period, of which 7 were excluded from this analysis due to insufficient data or 
missing folders. 
Patient and tumour characteristics 
Patient and tumour characteristics and treatment received are summarized in table 1.   
The predominant gender in this analysis was males with a male predominance of 
2,4:1.  The median age at diagnosis was 6 years (range 1-13).  Intracranial tumours 
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occurred more commonly than spinal tumours with intracranial ependymoma 
diagnosed in 43 patients (84,3%) and spinal ependymoma in 8 patients (15,7%).  Of 
the intracranial ependymomas, infratentorial tumour location was the predominant 
tumour location occurring in 32 patients (74,4%).  The tumours were low grade (1 
and 2) in 36 patients (70,6%) with the remaining 15 patients (29,4%) having high 
grade, anaplastic tumours.  Six patients (11,8%) had evidence of central nervous 
system (CNS) dissemination at diagnosis.   
Treatment parameters 
Gross total and near total resection was achieved in 22 patients (43,1%).  Subtotal 
resection was obtained in 25 patients (51%) and biopsy only was done in 4 patients 
(7,8%).  Documentation of the verification of extent of resection with postoperative 
imaging in patient’s folders was found in 40 patients (78,4%).  Thirty-nine patients 
(76,5%) received radiation therapy as a part of their treatment.  Of these, 19 patients 
(56,4%) received localized radiation therapy while the remaining 17 patients (43,6%) 
received craniospinal radiation therapy.  The median dose for localized radiation was 
54,00Gy (range 30,00Gy to 59,40Gy).  Two of the patients receiving localized 
radiation therapy received palliative radiation therapy, one for an extensive, 
inoperable spinal tumour (30,00Gy) and one patient with an infratentorial, anaplastic 
ependymoma who received only 40,00Gy, after deterioration in performance status 
postoperatively.  The median dose to the craniospinal axis was 32,00Gy (range 
30,00gy to 38,00Gy) and the median total dose of CSI was 52,00Gy.  Chemotherapy 
formed part of the treatment in 10 (19,6%) patients.  Eight of the patients were 3 
years and under at diagnosis and the chemotherapy was used to delay radiotherapy 
until the child was older in order to prevent neuro-cognitive side effects in the 
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developing brain.  The reason for chemotherapy in the two remaining patients is 
unclear.   
Outcomes and survival 
The 5 year OS was 63,3% for the whole series with a median follow up of 46 months 
(Figure 1).  The 5 year PFS for the whole series was 50,7%  (Figure 2). 
Increasing age was associated with an improved PFS (Figure 3).  The 5 year PFS for 
children > 3 years was 50,0 % and 27,7% for children ≤ to 3 years of age (p = 
0.0356).  Localised disease had an improved PFS with a median PFS of 73% 
compared to a median PFS of 13,3% (p = 0.046) in patients with extensive disease.  
Although increasing tumour grade showed a trend towards inferior OS, this failed to 
reach statistical significance (p = 0.253).  The 5 year OS for spinal tumour location 
was 85,3%, for supratentorial tumours was 75,3% and for infratentorial tumours was 
49,3%, however this failed to reach statistical significance (p = 0.291).   
GTR/NTR had a superior 5 year OS of 73,9% over subtotal resection with a 5 year 
OS of 56,7% (p = 0.0016) [figure 4].  Similarly an improved 5-year PFS of 70,3% 
was observed with GTR/NTR while subtotal resection had a value of 29,1% (p = 
<0.0001). Patients who received adjuvant radiation therapy had a significantly better 
outcome than those in whom radiation therapy was not given (p =0.0064, 5 year OS 
of 69,7% versus 37,5%[figure 5]; and p = <0.0001, median PFS of 87 months versus 
2 months).  The radiation therapy technique (localized versus CSI) given did not 
have a statistically significant impact on OS or PFS (p = 0.826 and p = 0.498).  
Treatment failure occurred in 17 patients (33,3%) with 7 patients diagnosed with a 
recurrence after a radiographic complete response and 10 patients with progressive 
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disease.  The median time to recurrence or progression was 20 months (range 2 to 73 
months).  The majority of recurrences/progression occurred early (within the first 3 
years) in the post treatment period (94,1%) with only 1 patient developing recurrence 
after 3 years  .The treatment failures all represented local failure only except for two 
patients (11,8%) who developed disease at another site in the brain and two patients 
(11,8%) who had local disease with evidence of metastatic deposits.  At the end of 
the study period, 4 (23,6%) of these patients still remained alive, 3 patients (17,6%) 
had been lost to follow up and 10 patients had demised (58,8%).  The median follow 
up the 4 patients who remain alive is 94 months. 
DISCUSSION 
 To the best of our knowledge, this is the first study giving insight into paediatric 
ependymoma management and outcomes in South Africa.  The rarity of this tumour 
is proved by the fact that only 58 patients were diagnosed over a 33-year period.  
Patient demographics of paediatric pateints diagnosed with ependymoma in this 
study are in keeping with international data, which shows a male preponderance for 
this tumour [2,3,6], that the majority of tumours occur intracranially [3,7,8] and 
show a low rate of tumour dissemenation at presenation [3,9,10] 
The 5 year OS and PFS for the whole series of 63,3% and 50,7% respectively which 
compared satisfactorily to other retrospective studies done over the same wide time 
frame as that spanning this study [2, 3, 9, 10]. 
A relapse rate of 33,3% observed in this study is lower then other reported studies 
reviewing patients with both intracranial and spinal ependymomas [3,7,8].  One of 
the factors that could account for this is could be the high number of patients lost to 
follow up and the short period of follow up.  Eleven patients (21,6%) were lost to 
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follow up within the first 3 years.  We found that the majority of treatment failures 
represented local failure and relapses tended to occur early in the treatment period 
(within 3 years).  This has been corroborated in other studies [3,9,11,12].  
 
GTR/NTR was achieved in 22 patients (43,1%) in this study.  The GTR rate has been 
reported as slightly higher in previously published papers, ranging between 50 and 
63% [3,9,10,13].  These numbers could be skewed by the fact that verification of the 
extent of resection was documented by postoperative imaging in only 40 patients 
(78,4%).  With the remaining patients who had postoperative imaging, we were 
unable to find the images to verify and measure residual tumour when present, and/or 
the post-operative residual was not documented in terms of cm3 in the patient folder 
and we had to rely on the neurosurgical report for the extent of resection.  This 
represents one of the limitations of this study.   
Although the prognostic significance of the extent of tumour resection was 
controversial in older papers, it has now been validated as one of the most important 
prognostic factors with gross total resection of tumour having the best outcomes 
[3,9,14,15].  Our study was able to confirm the latter finding.  The controversies in 
older papers were likely related to the lack of clear definitions for GTR, NTR and 
subtotal resection, as well as due to the lack of objective imaging criteria.   
 
The role of postoperative radiation therapy has been established for ependymomas 
and is based on historic studies that showed improved survival in patients treated 
with adjuvant radiation therapy compared to surgery alone [9,27]. Thirty-nine 
patients (76,5%) in this study received adjuvant radiation therapy and had a 
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statistically significant superior 5-year OS and PFS compared to subtotal resection 
and biopsy only.  Historically all patients who received radiotherapy for ependymal 
tumours, received craniospinal radiotherapy due to the risk of spinal seeding 
associated with this tumour.  Current guidelines for radiation therapy do not support 
the use of craniospinal irradiation for localized ependymoma.  Numerous studies 
support the finding that the major route of failure for localized ependymomas is a 
local recurrence [3,9,10,11].   In addition the low rate of metastatic relapse [3,8,9] 
does not warrant craniospinal irradiation, which in itself represents a higher risk of 
adverse effects due to the larger treatment volume irradiated.   We are in agreement 
with these current recommendations as this study showed no difference in survival 
based on whether patients received localized or craniospinal radiotherapy. 
Studies are currently looking at subsets of patients who may not require adjuvant 
radiotherapy or in whom radiotherapy can be deferred and used as part of salvage 
therapy. Hukin et al. published results of a prospective trial in which 10 patients with 
intracranial ependymoma who achieved GTR during surgery, received no adjuvant 
treatment [16].  Eight of these patients had supratentorial tumours and three patients 
tumours were anaplastic.  Seven (70%) of these patients remained tumour free after a 
median follow up of 48 months.  The remaining 3 patients were successfully 
salvaged (two with surgery and one with surgery and adjuvant radiotherapy).  This 
study has shown promising results in terms of possibly deferring radiotherapy in 
paediatric patients with supratentorial ependymoma, in whom a GTR has been 
radiologically confirmed. This strategy could spare patients for an indeterminate time 
from the neuro-cognitive and endocrine sequalae associated with radiotherapy.  
However this strategy does require close follow up with imaging in order to identify 
recurrences early and offer salvage therapy.  This study did not divide the patients 
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into molecular sub-groups, which would help identify the sub-groups of 
supratentorial, completely resected tumours in whom radiotherapy can be deferred.  
This should be looked at in a future study.   
 
The literature reports that younger children have worse outcomes [2,3,9,14,17].  This 
has been duplicated in our study in terms of PFS.  One of the reasons for this finding 
has been thought to be due to delaying radiation therapy in children who are 3 years 
of age and younger in order to prevent the neuro-cognitive sequelae of radiotherapy.  
Duffner at al. reported low 5-year survival rates of 25,7% in children less than 2 
years of age who received chemotherapy in order to delay radiotherapy [18].  
Similarly Nazar et al. reported a 5-year OS of 18,8% in children less than 2 
compared to a 5 year OS of 52,3% in children older than 2 years [17].  Another 
factor that may contribute to the adverse prognosis of younger patients is the delay in 
diagnosis in this group of patients.  A review of the presenting features of 40 children 
with ependymal tumours by Comi et al. found that the older children presented 
earlier and with smaller tumours [19].  
An association between younger age with high grade (anaplastic) tumours has been 
suggested [16].  It has been postulated that the difference in cytogenetic aberrations 
between younger and older patients may be responsible for the age related outcome 
[20].   
 
Ependymal tumours of the spine have been reported to have superior survival then 
intracranial ependymal tumours [2,7,8].  Although there was a trend for improved 
survival with spinal cord tumours in this analysis, this failed to reach statistical 
significance.  The prognostic significance of supratentorial versus infratentorial 
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tumours is less clear.  The literature has shown conflicting results in this regard.  
Numerous reviews have supported supratentorial tumours having a worse outcome 
[7,8,11] and it are postulated that this is related to the difficulty resecting these 
tumours for the following reasons.  Firstly, Fokes and Earle looked at the pathologic 
aspects of ependymomas and showed that supratentorial tumours often had an 
infiltrative growth into the brain parenchyma while infratentorial tumours grow 
exophytically, thus making surgical resection more difficult with supratentorial 
ependymomas [21].  Secondly, supratentorial tumours are more likely to be only 
partially encapsulated and lobulated, whereas infratentorial ependymomas are often 
completely encapsulated thus making complete resection easier. [22].  Cage et al. 
reported that infratentorial tumours have better outcomes as they cause symptoms 
sooner then their supratentorial counterparts and thus treatment can be initiated 
earlier [23].  Conversely, a worse outcome for infratentorial ependymomas was 
reported in other studies [24,25].  One hypothesis for this finding is that infratentorial 
tumours have a relatively high rate of brainstem and cerebellum invasion making 
GTR difficult.  Kritcheff et al reported a 34,6% rate of brainstem/cerebellum 
invasion.  Several papers found no difference in survival between these two regions 
[10,26,27,28]. 
In addition within each tumour site, subgroups have been identified that may 
influence the ease of surgical resectability.  Ernestus et al. identified midline 
supratentorial tumours as a subgroup associated with a lower resection rate and 
higher operative mortality [29].  Lateral recess tumours, which originate from the 
lateral part of the fourth ventricle infratentorially can be difficult to resect completely 
as they tend to displace or involve neurovascular structures [30].   
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Histological grading as a prognostic factor, still remains controversial.  There are a 
number of issues related to this.  Firstly there are major discrepancies between neuro-
pathologists with regard to tumour grading and the exact features that define 
anaplasia. Secondly, different publications use different grading systems in their 
reviews thus making interpretation of the literature difficult.  Lastly 
ependymoblastomas were previously classified with ependymomas and as they are 
aggressive tumours, they may have negatively influenced the outcomes of 
ependymomas in the past.  This study failed to show a statistically significant impact 
of tumour grade on outcome and this had been corroborated in other studies [31,32].  
Conversely other authors have reported a statistically significant effect of increasing 
tumour grade on outcomes [33, 34]. 
 
The limitations of this study include the retrospective nature of the review, 




This retrospective review adds weight to the already established finding that gross 
total resection improves survival in paediatric ependymoma patients and should be 
aimed for during surgery.  Although some authors are identifying, investigating and 
reporting on subgroups of patients that can be treated with surgery alone (such as 
supratetorial tumours that have been completely excised), this review showed 
statistically significantly improved outcomes with adjuvant radiotherapy and this 
should form an integral part of the treatment.  Localised radiotherapy is sufficient in 
treating patients with localized disease, reserving craniospinal for patients with 
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evidence of metastatic deposits.  The finding in this and other studies, that younger 
patients have a worse prognosis requires further investigation into the biological and 
cytogenetic aberrations in this age group which could account for this and allow 
possible revisions in treatment protocols in order to improve this the outcome in this 
group.  The results from this study are comparable to those around the world despite 
the limitations faced by South Africa as a developing country. 
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TABLES AND SURVIVAL CURVES 
PARAMETER NUMBER,  (%) OF PATIENTS  (51) 
Age (years) 
    Median 
    Range 
 
     ≤ 3 








    Male 
    Female 
 
34  (66,7%) 
17  (33,3%) 
Tumour location 
    Infratentorial     
    Supratentorial 
    Spinal 
 
32  (62,7%) 
11  (21,6%) 
8    (15,7%) 
WHO Histological grade  
    I  
    II 
    III 
 
2   (3,9%)   
34  (66,7%) 
15  (29,4%) 
Extent of disease, 
    Localised 
    Metastatic 
    Unknown/No staging 
 
40  (78,4%) 
6  (11,8%) 
5    (9,8%) 
Treatment modality 
    Surgery alone 
    Surgery and chemotherapy 
    Surgery and radiotherapy 
    Surgery and chemotherapy and  
     radiotherapy 
 
8  (15,7%) 
4  (7,8%) 
33  (64,7%) 
6  (11,8%) 
Table 1 











Overall survival of 51 patients diagnosed with ependymoma. 
 















Figure 2  
Progression free survival of 51 patients diagnosed with ependymoma. 
Figure 3 
Progression free survival of patients ≤3 years old and > 3 years of age. 




























≤ 3 years of age
> 3 years of age
p = 0.0356
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Figure 4  
Overall survival of patients according to extent of surgical resection. 
Figure 5 
Overall survival of patients according to whether they received adjuvant 
radiation therapy or not. 





































LIST OF ABBREVIATIONS 
• CSF:  Cerebrospinal fluid
• CSI:  Craniospinal irradiation
• ECOG:  Eastern Coopertive Oncology Group
• EFS:  Event free survival
• EPR:  Electronic patient registry
• GSH: Groote Schuur Hospital
• GTR:  Gross total resection
• NHLS:  National Health Laboratory Service
• NTR:  Near total resection
• OS:  Overall survival
• PFS:  Progression free survival
• RCCH:  Red Cross Childrens Hospital
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Guideline word limit: 4 000 words 
Research articles describe the background, methods, results and conclusions of an 
original research study. The article should contain the following sections: 
introduction, methods, results, discussion and conclusion, and should include a 
structured abstract (see below). The introduction should be concise – no more than 
three paragraphs – on the background to the research question, and must include 
references to other relevant published studies that clearly lay out the rationale for 
conducting the study. Some common reasons for conducting a study are: to fill a gap 
in the literature, a logical extension of previous work, or to answer an important 
clinical question. If other papers related to the same study have been published 
previously, please make sure to refer to them specifically. Describe the study 
methods in as much detail as possible so that others would be able to replicate the 
study should they need to. Results should describe the study sample as well as the 
findings from the study itself, but all interpretation of findings must be kept in the 
discussion section, which should consider primary outcomes first before any 
secondary or tertiary findings or post-hoc analyses. The conclusion should briefly 
summarise the main message of the paper and provide recommendations for further 
study. 
Select figures and tables for your paper carefully and sparingly. Use only those 
figures that provided added value to the paper, over and above what is written in the 
text. 
Do not replicate data in tables and in text . 
Structured abstract 
• This should be 250-400 words, with the following recommended headings:
◦ Background: why the study is being done and how it relates to other
published work. 
◦ Objectives: what the study intends to find out
◦ Methods: must include study design, number of participants, description of
the intervention, primary and secondary outcomes, any specific 
analyses that were done on the data. 
◦ Results: first sentence must be brief population and sample description;
outline the results according to the methods described. Primary 
outcomes must be described first, even if they are not the most 
significant findings of the study. 
◦ Conclusion: must be supported by the data, include recommendations for
further study/actions. 
• Please ensure that the structured abstract is complete, accurate and clear and has
been approved by all authors. 
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• Do not include any references in the abstracts.
Here is an example of a good abstract. 
Main article 
All articles are to include the following main sections: Introduction/Background, 
Methods, Results, Discussion, Conclusions. 
The following are additional heading or section options that may appear within these: 
• Objectives (within Introduction/Background): a clear statement of the main aim of
the study and the major hypothesis tested or research question posed 
• Design (within Methods): including factors such as prospective, randomisation,
blinding, placebo control, case control, crossover, criterion standards for 
diagnostic tests, etc. 
• Setting (within Methods): level of care, e.g. primary, secondary, number of
participating centres. 
• Participants (instead of patients or subjects; within Methods): numbers entering
and completing the study, sex, age and any other biological, behavioural, 
social or cultural factors (e.g. smoking status, socioeconomic group, 
educational attainment, co-existing disease indicators, etc)that may have an 
impact on the study results. Clearly define how participants were enrolled, 
and describe selection and exclusion criteria. 
• Interventions (within Methods): what, how, when and for how long. Typically for
randomised controlled trials, crossover trials, and before and after studies. 
• Main outcome measures (within Methods): those as planned in the protocol, and
those ultimately measured. Explain differences, if any. 
Results 
• Start with description of the population and sample. Include key characteristics of
comparison groups. 
• Main results with (for quantitative studies) 95% confidence intervals and, where
appropriate, the exact level of statistical significance and the number need to 
treat/harm. Whenever possible, state absolute rather than relative risks. 
• Do not replicate data in tables and in text.
• If presenting mean and standard deviations, specify this clearly. Our house style is
to present this as follows: 
• E.g.: The mean (SD) birth weight was 2 500 (1 210) g. Do not use the ± symbol
for mean (SD). 
• Leave interpretation to the Discussion section. The Results section should just
report the findings as per the Methods section. 
Discussion 
Please ensure that the discussion is concise and follows this overall structure – sub-
headings are not needed: 
• Statement of principal findings
• Strengths and weaknesses of the study
• Contribution to the body of knowledge
• Strengths and weaknesses in relation to other studies
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• The meaning of the study – e.g. what this study means to clinicians and
policymakers 
• Unanswered questions and recommendations for future research
Conclusions 
This may be the only section readers look at, therefore write it carefully. Include 
primary conclusions and their implications, suggesting areas for further research if 
appropriate. Do not go beyond the data in the article. 
Editorials 
Guideline word limit: 1 000 words 
These opinion or comment articles are usually commissioned but we are happy to 
consider and peer review unsolicited editorials. Editorials should be accessible and 
interesting to readers without specialist knowledge of the subject under discussion 
and should have an element of topicality (why is a comment on this issue relevant 
now?) There should be a clear message to the piece, supported by evidence. 
Please make clear the type of evidence that supports each key statement, e.g.: 
• expert opinion





CME is intended to provide readers with practical, up-to-date information on medical 
and related matters. It is aimed at those who are not specialists in the field. 
From January 2016, all CME articles will be printed in full in the SAMJ. Please try to 
adhere strictly to the guidelines on word count as we have a page limit for the print 
issue of the SAMJ. We reserve the right to place some tables and reference lists 
online if this is necessary for space. 
In practice, this means that each CME topic usually covers two issues of the print 
issue of the SAMJ. 
The guest editor, in consultation with the editor, is responsible for convening a team 
of authors, deciding on the subjects to be covered and for reviewing the manuscripts 
submitted. The suggestion is for 4 - 5 articles, although there is some room for 
flexibility contingent on discussions with the editor. 
For queries about these guidelines please feel free to contact the CME editor, Dr 
Bridget Farham, by email (ugqirha@iafrica.com) or telephone (+27 (0)21 789 2331). 
Review process 
The guest editor reviews the articles and returns them to the CME editor for review 
and final approval. 
Guest editorials 
Guideline word limit: 1 000 words 
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• Include the guest editor’s personal details (qualifications, positions, affiliation, e-
mail address, and a short personal profile (50words)). 
• If possible, include a photograph of the author(s) at high enough resolution for
print. It is preferable to provide two guest editorials, one for each issue, so 
that the content of the articles in each issue is covered. 
Articles 
Guideline word limit: 2 000 - 3 000 words 
• Each article requires an abstract of ±200 words.
• The editor reserves the right to shorten articles but will send a substantially
shortened article back for author approval. 
Personal details 
Please supply: Your qualifications, position and affiliations and MP number (used 
for CPD points); Address, telephone number and fax number, and your e-mail 
address; and a short personal profile (50words)and a few words about your current 
fields of interest. 
In Practice 
Guideline word limit: 2 000 - 3 000words 
This section includes articles that would previously have been accepted into the 
Forum section, and case reports. 
In practice articles are those that draw attention to specific issues of clinical, 
economic or political interest regarding medicine and healthcare in southern Africa. 




• Issues in medicine
• Issues in public health
• Healthcare delivery
• Consensus/Position statement
• Medicine and the environment
• Medicine and the law
• Cochrane corner
An In Practice article should follow the following format – sub-headings are not 
necessary, but may be used for clarity: 
• Author affiliations and qualifications: to be the same as for Research. Provide all
authors’ names and initials, qualifications and full affiliations, and 
corresponding author. 
• Short abstract: does not need to be structured, but should capture the essential
features of the article 
• Introduction: the reason for the article and the issue being addressed
• Recent research, discussion, local policy around the issue – include your own
research where appropriate 
• All statements should be referenced and, if opinion only, this should be stated
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• Discussion: how this article adds to the discussion around a particular topic
• If a clinical practice or policy point is at issue, this needs to be emphasised, using a
box with highlights if appropriate. 
Essentially In practice is an opportunity for a more discursive approach to topics of 
clinical, economic or political importance in southern African health systems. It is 
not an opportunity to put forward unsubstantiated opinions! 
Case reports 
The SAMJ has recently started to accept case reports. The cases must come from 
Africa, preferably southern Africa unless the condition is common to all African 
countries, and must be either a completely new description of a clinical condition or 
result (use Google!) or a case that highlights important practice or management 
issues. 
Please use the following format for case reports: 
• Title of case: do not include the words ‘a case report’ in the title
• Summary/abstract:  up to 150 words summarising the case presentation and
outcome 
• Background: why is this case important and why did you write it up?
• Case presentation: presenting features, medical, social, family history as
appropriate 
• Case management: should be according to best practice, and if not, please explain
why 
• Investigations, if relevant: save space by simply saying ‘normal’ if, for example,
renal function was completely normal, rather than listing normal results, 
highlight the abnormal – or indeed the normal if this is clinically significant 
• Differential diagnosis, if relevant
• Treatment, if relevant
• Outcome and follow-up
• Discussion – a VERY BRIEF review of similar published cases
• Teaching points: 3 - 5 bullet points
• References: as per the SAMJ house style
• Tables and figures: keep to a minimum. Use clinical images where relevant – we
need hi-res versions for print, and identifiable persons must have a consent 
form 
• Patient consent: please include a statement about patient consent to a written case
report. This should be uploaded as a supplementary file. 
Clinical trials 
Guideline word limit: 4000 words 
As per the recommendations published by the International Committee of Medical 
Journal Editors (ICMJE), clinical trial research is any research that assigns 
individuals to an intervention, with or without a concurrent comparison/control 
group to study the cause-and-effect relationship between the intervention and health 
outcomes. All clinical trials should be registered with the appropriate national 
clinical trial registry (or any international primary register, if relevant), and the trial 
registration number should be cited at the end of the abstract. Since 1st December 
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2005, all clinical trials conducted in South Africa have been required to be registered 
in the South African National Clinical Trials Register. The SAMJ therefore requires 
that clinical trials be registered in the relevant public trials registry at or before the 
time of first patient enrollment as a condition for publication. The trial registry name 
and registration number must be included in the manuscript. 
Please refer to the general guidelines for all papers at the top of this article for 
additional requirements with respect to ethics approval, funding, author 
contributions, etc. The format of original research articles should be followed for 
reporting of clinical trial results. 
Review articles 
Guideline word limit: 4 000 words 
These are welcome, but should be either commissioned or discussed with the Editor 
before submission. A review article should provide a clear, up-to-date account of the 
topic and be aimed at non-specialist hospital doctors and general practitioners. 
Please ensure that your article includes: 
• Abstract: unstructured, of about 100-150 words, explaining the review and why it
is important 
• Methods: Outline the sources and selection methods, including search strategy and
keywords used for identifying references from online bibliographic 
databases. Discuss the quality of evidence. 
• When writing: clarify the evidence you used for key statements and the strength of
the evidence. Do not present statements or opinions without such evidence, or 
if you have to, say that there is little or no evidence and that this is opinion. 
Avoid specialist jargon and abbreviations, and provide advice specific to 
southern Africa. 
• Personal details: Please supply your qualifications, position and affiliations and
MP number (used for CPD points); address, telephone number and fax 
number, and your e-mail address; and a short personal profile (50 words) and 
a few words about your current fields of interest. 
Correspondence (Letters to the Editor) 
Guideline word limit: 500 words 
Letters to the editor should relate either to a paper or article published by the SAMJ 
or to a topical issue of particular relevance to the journal’s readership 
• May include only one illustration or table
• Must include a correspondence address.
Book reviews 
Guideline word limit: 400 words 
Should be about 400 words and must be accompanied by the publication details of 




Guideline word limit: 400 words 
Should be offered within the first year of the practitioner’s death, and may be 
accompanied by a photograph. 
Guidelines 
Guidelines should always be discussed with the Editor prior to submission. 
Because of the intensive review process required to ensure Guidelines are 
independent, evidence-based and free from commercial bias, they are usually 
published as a supplement to the SAMJ, the costs of which must be covered by 
sponsorship, advertising or payment by the guideline authors/association. We will 
provide a quote based on the expected length of the guideline and whether it is to 
appear online only, or in print, which must be accepted by the body putting the 
guidelines together before submitting the work to the SAMJ. 
The Editor reserves the right to determine the scheduling of supplements. 
Understandably, a delay in publication must be anticipated dependent upon editorial 
workflow. 
All guidelines should be structured according to Agree II. 
Please access this website before putting the guidelines together, download the Agree 
11 instrument and use this to put the guidelines together. 
All submitted guidelines will be sent to the local Agree II appraisal committee for 
review and must be endorsed by an appropriate body prior to consideration and all 
conflicts of interest expressed. 
A structured abstract not exceeding 400 words (recommended sub-
headings: Background, Recommendations, Conclusion) is required. Sections and 
sub-sections must be numbered consecutively (e.g. 1. Introduction; 1.1 Definitions; 
2.etc.) and summarised in a Table of Contents.
Illustrations/photos/scans 
• If illustrations submitted have been published elsewhere, the author(s) should
provide consent to republication obtained from the copyright holder. 
• Figures must be numbered in Arabic numerals and referred to in the text e.g. '(Fig.
1)'. 
• Each figure must have a caption/legend: Fig. 1. Description (any abbreviations in
full). 
• All images must be of high enough resolution/quality for print.
• All illustrations (graphs, diagrams, charts, etc.) must be in PDF form.
• Ensure all graph axes are labelled appropriately, with a heading/description and
units (as necessary) indicated. Do not include decimal places if not necessary 
e.g. 0; 1.0; 2.0; 3.0; 4.0 etc.
• Scans/photos showing a specific feature e.g. Intermediate magnification
micrograph of a low malignant potential (LMP) mucinous ovarian tumour. 
(H&E stain). –include an arrow to show the tumour. 
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• Each image must be attached individually as a 'supplementary file' upon
submission (not solely embedded in the accompanying manuscript) and 
named Fig. 1, Fig. 2, etc. 
Tables 
• Tables should be constructed carefully and simply for intelligible data
representation. Unnecessarily complicated tables are strongly discouraged. 
• Embed/include each table in the manuscript Word file - do not provide separately
as supplementary files. 
• Number each table in Arabic numerals (Table 1, Table 2, etc.) and refer to
consecutively in the text. 
• Tables must be cell-based (i.e. not constructed with text boxes or tabs) and
editable. 
• Ensure each table has a concise title and column headings, and include units where
necessary. 
• Footnotes must be indicated with consecutive use of the following symbols: * † ‡
§ ¶ || then ** †† ‡‡ etc.
Do not: Use [Enter] within a row to make ‘new rows’: 
Rather: 
Each row of data must have its own proper row: 
Do not: use separate columns for n and %: 
Rather: 
Combine into one column, n (%): 
Do not: have overlapping categories, e.g.: 
Rather: 
Use <> symbols or numbers that don’t overlap: 
References 
NB: Only complete, correctly formatted reference lists in Vancouver style will be 
accepted. Reference lists must be generated manually and not with the use of 
reference manager software. Endnotes must not be used. 
• Authors must verify references from original sources.
• Citations should be inserted in the text as superscript numbers between square
brackets, e.g. These regulations are endorsed by the World Health 
Organization,[2] and others.[3,4-6] 
• All references should be listed at the end of the article in numerical order of
appearance in the Vancouver style (not alphabetical order). 
• Approved abbreviations of journal titles must be used; see the List of Journals in
Index Medicus. 
• Names and initials of all authors should be given; if there are more than six
authors, the first three names should be given followed by et al. 
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• Volume and issue numbers should be given.
• First and last page, in full, should be given e.g.: 1215-1217 not 1215-17.
• Wherever possible, references must be accompanied by a digital object identifier
(DOI) link). Authors are encouraged to use the DOI lookup service offered 
by CrossRef: 
◦ On the Crossref homepage, paste the article title into the ‘Metadata search’
box. 
◦ Look for the correct, matching article in the list of results.
◦ Click Actions > Cite
◦ Copy the DOI between { }, which will always start with 10.
◦ Provide as follows: DOI:10.7196/07294.937.98x
Some examples: 
• Journal references: Price NC, Jacobs NN, Roberts DA, et al. Importance of asking
about glaucoma. Stat Med 1998;289(1):350-355. DOI:10.1000/hgjr.182 
• Book references: Jeffcoate N. Principles of Gynaecology. 4th ed. London:
Butterworth, 1975:96-101. 
• Chapter/section in a book: Weinstein L, Swartz MN. Pathogenic Properties of
Invading Microorganisms. In: Sodeman WA, Sodeman WA, eds. Pathologic 
Physiology: Mechanisms of Disease. Philadelphia: WB Saunders, 1974:457-
472. 
• Internet references: World Health Organization. The World Health Report 2002 -
Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002. 
http://www.who.int/whr/2002 (accessed 16 January 2010). 
• Legal references
• Government Gazettes:
National Department of Health, South Africa. National Policy for Health Act, 1990
(Act No. 116 of 1990). Free primary health care services. Government Gazette No.
17507:1514. 1996.
In this example, 17507 is the Gazette Number. This is followed by :1514 - this is the
notice number in this Gazette.
• Provincial Gazettes:
Gauteng Province, South Africa; Department of Agriculture, Conservation,
Environment and Land Affairs. Publication of the Gauteng health care waste
management draft regulations. Gauteng Provincial Gazette No. 373:3003, 2003.
• Acts:
South Africa. National Health Act No. 61 of 2003.
• Regulations to an Act:
South Africa. National Health Act of 2003. Regulations: Rendering of clinical
forensic medicine services. Government Gazette No. 35099, 2012. (Published under
Government Notice R176).
• Bills:
South Africa. Traditional Health Practitioners Bill, No. B66B-2003, 2006.
• Green/white papers:
South Africa. Department of Health Green Paper: National Health Insurance in South
Africa. 2011.
• Case law:
Rex v Jopp and Another 1949 (4) SA 11 (N)
Rex v Jopp and Another:  Name of the parties concerned
1949: Date of decision (or when the case was heard)
66	
(4): Volume number 
SA: SA Law Reports 
11: Page or section number 
(N): In this case Natal - where the case was heard. Similarly, (C) woud indicate 
Cape, (G) Gauteng, and so on. 
NOTE: no . after the v 
• Other references (e.g. reports) should follow the same format: Author(s). Title.
Publisher place: Publisher name, year; pages. 
• Cited manuscripts that have been accepted but not yet published can be included as
references followed by '(in press)'. 
• Unpublished observations and personal communications in the text must not
appear in the reference list. The full name of the source person must be 
provided for personal communications e.g. '...(Prof. Michael Jones, personal 
communication)'. 
From submission to acceptance 
Submission and peer-review 
To submit an article: 
• Please ensure that you have prepared your manuscript in line with the SAMJ
requirements. 
• All submissions should be submitted via Editorial Manager
• The following are required for your submission to be complete:
◦ Anonymous manuscript (unless otherwise stated)
◦ Author Agreement form [forthcoming]
◦ Manuscript
◦ Any supplementary files: figures, datasets, patient consent form,
permissions for published images, etc. 
• Once the submission has been successfully processed on Editorial Manager, it will
undergo a technical check by the Editorial Office before it will be assigned to 
an editor who will handle the review process. If the author guidelines have 
not been appropriately followed, the manuscript may be sent back to the 
author for correcting. 
Peer-review process 
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Article Processing Charges 
There is currently no article-processing charge (APC), also known as page fees, for 
the publication of manuscripts. This is subject to change however. 
As no pay-to-view fees are charged for access to SAMJ articles, publication costs – 
including those of peer review management, journal production and online/print 
publication – will in future need to be absorbed by the introduction of APC to 
authors, institutions or funders of accepted articles. Waiver requests may be 
considered on a case-by-case basis and at the sole discretion of HMPG. Further 
information will be provided in due course. 
Please refer to the section on ‘Sponsored Supplements’ [hyperlink to relevant text 
above] regarding the publication of supplements, where a charge is currently 
applicable. Queries can be directed to Dianes@hmpg.co.za or Claudian@hmpg.co.za 
Production process 
The following process should usually take between 4 - 6 weeks: 
1 An accepted manuscript is passed to a Managing Editor to assign to a copyeditor 
(CE). 
2 The CE copyedits in Word, working on house style, format, 
spelling/grammar/punctuation, sense and consistency, and preparation for 
typesetting. 
3 If the CE has an author queries, he/she will contact the corresponding author and 
send them the copyedited Word doc, asking them to solve the queries by 
means of track changes or comment boxes. 
4 The authors are typically asked to respond within 1-3 days. Any 
comments/changes must be clearly indicated e.g. by means of track changes. 
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Do not work in the original manuscript - work in the copyedited file sent to 
you and make your changes clear. 
5 The CE will finalise the article and then it will be typeset. 
6 Once typeset, the CE will send a PDF of the file to the authors to complete their 
final check, while simultaneously sending to the 2nd-eye proofreader. 
7 The authors are typically asked to complete their final check and sign-off within 1-
2 days. No major additional changes can be accommodated at this point. 
8 The CE implements the authors’ and proofreader’s mark-ups, finalises the file, and 
prepares it for the upcoming issue. 
Changing contact details or authorship 
Please notify the Editorial Department of any contact detail changes, including 
email, to facilitate communication. 
Publication 
Online v. print 
The SAMJ is an online journal. The online version of the journal is the one that has 
the widest circulation, is indexed by bibliographic databases including PubMed and 
SciELO, and is accessible in academic libraries. A printed edition , containing 
material selected by the Editor is also published each month and distributed to the 
membership of the South African Medical Association. 
Online 
• The full text of all accepted articles is published in full online, open access, within
4 - 6 weeks of acceptance. 
• Citation information of each article is based on its online publication.
• You may want to make use of the advantages of online publication e.g. specify
web links to other sources, images, data or even a short video. 
Print 
• Not all articles will be selected for print.
• An article may be selected for print in a different month from that in which it was
published online. 
• Research articles will appear in abstract form only, if selected for a print edition.
Errata and retractions 
Errata 
Should you become aware of an error or inaccuracy in yours or someone else’s 
contribution after it has been published, please inform us as soon as possible via an 
email to publishing@hmpg.co.za,including the following details: 
• Journal, volume and issue in which published
• Article title and authors
• Description of error and details of where it appears in the published article
• Full detail of proposed correction and rationale
We will investigate the issue and provide feedback. If appropriate, we will correct 
the web version immediately, and will publish anerratum  in the next issue. The 
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correction will be indexed, as PubMed has a function for linking errata back to the 
original article. All investigations will be conducted in accordance with guidelines 
provided by the Committee on Publication Ethics (COPE). 
Retractions 
Retraction of an article is the prerogative of either the original authors or the editorial 
team of HMPG. Should you wish to withdraw your article before publication, we 
need a signed statement from all the authors. 
Should you wish to retract your published article, all authors have to agree in writing 
before publication of the retraction. 
Send an email to publishing@hmpg.co.za, including the following details: 
• Journal, volume and issue to which article was submitted/in which article was
published 
• Article title and authors
• Description of reason for withdrawal/retraction.
We will make a decision on a case-by-case basis upon review by the editorial 
committee in line with international best practices. Comprehensive feedback will be 
communicated with the authors with regard to the process. In case where there is any 
suspected fraud or professional misconduct, we will follow due process as 
recommended by the Committee on Publication Ethics (COPE), and in liaison with 
any relevant institutions. 
When a retraction is published, it will be linked to the original article. 
Indexing 
The SAMJ has an impact factor of 1.712. 
Published articles are covered by the following major indexing services. As such 
articles published in the SAMJ are immediately available to all users of these 
databases, guaranteed a global and African audience: 
• Index Medicus (Medline/PubMed)
• ExcerptaMedica (EMBASE)
• Biological Abstracts (BIOSIS)
• Science Citation Index (SciSearch)







Contact claudian@hmpg.co.za for information on submitting ad hoc/commissioned 
supplements, including guidelines, conference/congress abstracts, Festschrifts, etc. 
Submission Preparation Checklist 
As part of the submission process, authors are required to check off their 
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submission's compliance with all of the following items, and submissions may be 
returned to authors that do not adhere to these guidelines. 
1 Named authors consent to publication and meet the requirements of authorship as 
set out by the journal. 
2 The submission has not been previously published, nor is it before another journal 
for consideration. 
3 The text complies with the stylistic and bibliographic requirements in Author 
Guidelines. 
4 The manuscript is in Microsoft Word or RTF document format. The text is single-
spaced, in 12-point Times New Roman font, and contains no unnecessary 
formatting. 
5 Illustrations/figures are high resolution/quality (not compressed) and in an 
acceptable format (preferably TIFF or PNG). These must be submitted 
individually as 'supplementary files' (not solely embedded in the manuscript). 
6 For illustrations/figures or tables that have been published elsewhere, the author 
has obtained written consent to republication from the copyright holder. 
7 Where possible, references are accompanied by a digital object identifier (DOI) 
and PubMed ID (PMID)/PubMed Central ID (PMCID). 
8 An abstract has been included where applicable. 
9 The research was approved by a Research Ethics Committee (if applicable) 
10 Any conflict of interest (or competing interests) is indicated by the author(s). 
Copyright Notice 
The South African Medical Journal (SAMJ) reserves copyright of the material 
published. The work is licensed under a Creative Commons Attribution - 
Noncommercial Works License. Material submitted for publication in the SAMJ is 
accepted provided it has not been published or submitted for publication elsewhere. 
The SAMJ does not hold itself responsible for statements made by the authors. 
Privacy Statement 
The SAMJ is committed to protecting the privacy of the users of this journal website. 
The names, personal particulars and email addresses entered in this website will be 
used only for the stated purposes of this journal and will not be made available to 
third parties without the user’s permission or due process. Users consent to receive 
communication from the SAMJ for the stated purposes of the journal. Queries with 
regard to privacy may be directed to publishing@hmpg.co.za. 
